Ankush Bhatia

ORCID: 0000-0001-5292-2822
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glioma Diagnosis and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • Brain Metastases and Treatment
  • CNS Lymphoma Diagnosis and Treatment
  • Histiocytic Disorders and Treatments
  • MRI in cancer diagnosis
  • Cancer Genomics and Diagnostics
  • Leprosy Research and Treatment
  • Mycobacterium research and diagnosis
  • Peripheral Neuropathies and Disorders
  • Lymphoma Diagnosis and Treatment
  • interferon and immune responses
  • CAR-T cell therapy research
  • Eosinophilic Disorders and Syndromes
  • Cancer, Hypoxia, and Metabolism
  • Polyomavirus and related diseases
  • Cancer Immunotherapy and Biomarkers
  • Cancer Treatment and Pharmacology
  • Ocular Diseases and Behçet’s Syndrome
  • Meningioma and schwannoma management
  • Medical Imaging Techniques and Applications
  • Cancer Research and Treatments
  • Chronic Lymphocytic Leukemia Research
  • Complex Network Analysis Techniques
  • Ferroptosis and cancer prognosis

Memorial Sloan Kettering Cancer Center
2017-2024

University of Wisconsin–Madison
2021-2024

University of Wisconsin Carbone Cancer Center
2023-2024

The University of Texas Health Science Center at Houston
2021-2022

University of Houston
2022

Memorial Hermann
2021

Institut de Chimie et des Matériaux Paris-Est
2020

Université Paris-Est Créteil
2020

Centre National de la Recherche Scientifique
2020

Rush University Medical Center
2007-2016

The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of the following adult CNS cancers: glioma (WHO grade 1, WHO 2–3 oligodendroglioma [1p19q codeleted, IDH- mutant], 2–4 mutant astrocytoma, 4 glioblastoma), intracranial and spinal ependymomas, medulloblastoma, limited extensive brain metastases, leptomeningeal non–AIDS-related primary lymphomas, metastatic spine tumors, meningiomas, cord tumors. information contained in algorithms principles sections are...

10.6004/jnccn.2023.0002 article EN Journal of the National Comprehensive Cancer Network 2023-01-01

Abstract Background Melanoma brain metastases historically portend a dismal prognosis, but recent advances in immune checkpoint inhibitors (ICIs) have been associated with durable responses some patients. There are no validated imaging biomarkers outcomes patients melanoma receiving ICIs. We hypothesized that radiomic analysis of magnetic resonance images (MRIs) could identify higher-order features survival. Methods Between 2010 and 2019, we retrospectively reviewed who received ICI. After...

10.1093/neuonc/noz141 article EN Neuro-Oncology 2019-10-11

Abstract Background Erdheim–Chester disease (ECD) is a rare histiocytic neoplasm characterized by recurrent alterations in the MAPK (mitogen-activating protein kinase) pathway. The existing literature about neuro-oncological spectrum of ECD limited. Methods We present retrospective clinical, radiographic, pathologic, molecular, and treatment data from 30 patients with neurohistiocytic involvement treated at tertiary center. Results Median age was 52 years (range, 7–77), 20 (67%) were male....

10.1093/neuonc/noaa008 article EN Neuro-Oncology 2020-01-14

Single-agent dabrafenib for BRAF V600E-mutated histiocytosisLangerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are clonal disorders of the monocyte/macrophage dendritic lineages characterized by infiltration histiocytes, acute chronic inflammation, fibrosis that can involve multiple organ systems cause a wide range clinical manifestations.][5] Vemurafenib recently obtained approval Food Drug administration treatment V600E -mutated ECD on basis VE-BASKET trial. 6However,...

10.3324/haematol.2017.185298 article EN cc-by-nc Haematologica 2018-02-22

Abstract Purpose: Isocitrate dehydrogenase–mutant (IDH-mt) gliomas are incurable primary brain tumors characterized by a slow-growing phase over several years followed rapid-growing malignant phase. We hypothesized that tumor volume growth rate (TVGR) on MRI may act as an earlier measure of clinical benefit during the active surveillance period. Experimental Design: integrated three-dimensional volumetric measurements with clinical, radiologic, and molecular data in retrospective cohort...

10.1158/1078-0432.ccr-23-1180 article EN Clinical Cancer Research 2023-11-01

Lymphomatous brain lesions can represent primary central nervous system (CNS) lymphoma or secondary involvement as part of systemic disease (SCNSL). In this study, we characterize staging evaluations in a large patient cohort with newly-diagnosed lymphomas, to determine the frequency SCNSL and malignancies. This retrospective review includes 262 patients lymphomatous CNS evaluated at Memorial Sloan Kettering Cancer Center between 2006 2018. Staging procedures included PET scans 180 (69%)...

10.1080/10428194.2018.1563294 article EN Leukemia & lymphoma/Leukemia and lymphoma 2019-01-10

We investigated the incidence of viral, fungal, bacterial, and parasitic infections observed in 57 patients with central nervous system lymphoma after thiotepa, busulfan, cyclophosphamide-conditioned autologous stem cell transplantation (TBC-ASCT) 79 systemic non-Hodgkin traditional carmustine, etoposide, cytarabine, melphalan–conditioned ASCT (BEAM-ASCT). Twenty (35%) TBC-ASCT had detectable viremia human herpesvirus 6, cytomegalovirus, adenovirus, or BK virus, versus 9 (11%) BEAM-ASCT...

10.1016/j.bbmt.2018.04.013 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2018-04-18

Patients with grade 2 glioma exhibit highly variable survival. Re-irradiation for recurrent disease has limited mature clinical data. We report treatment results of pulsed reduced-dose rate (PRDR) radiation patients glioma.

10.1093/noajnl/vdae073 article EN cc-by-nc Neuro-Oncology Advances 2024-01-01

Abstract Background Lumbar puncture (LP) is a frequently performed diagnostic and therapeutic procedure in oncology patients. Transfusing to minimum preprocedural platelet threshold of 50 × 10 9 /L widely upheld without good quality evidence. The objective was compare the outcomes LPs with platelets above below this threshold. An increased risk adverse events patients lower counts not expected. As corollary, transfusion reaction rates incurred by transfusing recommended are also reported....

10.1111/trf.15988 article EN Transfusion 2020-08-18

Abstract Leptomeningeal metastases/diseases (LMDs) are a late-stage complication of solid tumor or hematologic malignancies. LMD is spread cancer cells to the layers leptomeninges (pia and arachnoid maters) subarachnoid space seen in 3 5% patients. It disseminated disease which carries with it significant neurologic morbidity mortality. Our understanding pathophysiology currently lacking; however, advances being made. As our knowledge pathogenesis has improved, treatment strategies have...

10.1055/s-0043-1776996 article EN Seminars in Neurology 2023-11-21

A persona in a social network is defined as the person's activities and attributes seen by others. And community group of users that which share common interests are most likely to interact with each other network. For detection, user's its connections network, both play an important role. These communities help personalization service/product accommodates specific generalizing service for all community.

10.1109/cit.2016.24 article EN 2016-12-01

Abstract BACKGROUND Glioblastoma (GBM) is the most common primary brain malignancy in adults. Standard of care (SOC) for suspected GBM begins with maximal safe resection followed by adjuvant radiotherapy and temozolomide, maintenance temozolomide. Imvax has utilized its Goldspire™ platform to create IGV-001, an autologous biologic-device combination product treatment newly diagnosed (ndGBM). IGV-001 consists tumor cells antisense oligonucleotide against IGF-1R mRNA (IMV-001), irradiated...

10.1093/neuonc/noae144.222 article EN Neuro-Oncology 2024-10-01

Abstract Standard of care (SOC) for ndGBM begins with maximal safe resection followed by adjuvant radiotherapy and temozolomide, maintenance temozolomide. IGV-001 is an autologous biologic-device combination immunotherapy the treatment that consists GBM tumor cells antisense oligonucleotide against IGF-1R mRNA, irradiated administered via biodiffusion chambers implanted in abdomen. In a phase 1b study, was well tolerated without unexpected adverse events subjects ndGBM. Multiple efficacy...

10.1093/neuonc/noae165.0347 article EN Neuro-Oncology 2024-11-01
Coming Soon ...